Company: TELO
Filing Date: 2025-08-14
Form Type: 10-Q
Source: 0001641172-25-023970
Chunk: 54

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-08-14
Form: 10-Q
Item: Item 8
Chunk 54
---
 strategic plans for our business, product candidates, and technology;

●
the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and technology;

●
developments relating to our competitors and our industry; and

●
other risks and factors listed under “Risk Factors” and elsewhere in our Annual Report on Form 10-K for the year ended December
31, 2024.

Given
the risks and uncertainties set forth in this quarterly report, you are cautioned not to place undue reliance on such forward-looking
statements. The forward-looking statements contained in this quarterly report are not guarantees of future performance and our actual
results of operations, financial condition, and liquidity, and the development of the industry in which we operate, may differ materially
from the forward-looking statements contained in this quarterly report. In addition, even if our results of operations, financial condition
and liquidity, and events in the industry in which we operate are consistent with the forward-looking statements contained in this quarterly
report, they may not be predictive of results or developments in future periods.

Any
forward-looking statement that we make in this quarterly report speaks only as of the date of such statement. Except as required by federal
securities laws, we do not undertake any obligation to update or revise, or to publicly announce any update or revision to, any of the
forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this quarterly report.

19

PART
II. OTHER INFORMATION

Item
1. Legal Proceedings

From
time to time, we may be named in claims arising in the ordinary course of business. Currently, no legal proceedings, government actions,
administrative actions, investigations, or claims are pending against us or involve us that, in the opinion of our management, could
reasonably be expected to have a material adverse effect on our business and financial condition.

We
anticipate that we will expend significant financial and managerial resources in the defense of our intellectual property rights in the
future if we believe that our rights have been violated. We also anticipate that we will expend significant financial and managerial
resources to defend against claims that our products and services infringe upon the intellectual property rights of third parties.

Item
1A. Risk Factors.

As
a smaller reporting company, information under this “Item 1A. Risk Factors” is not required to be presented.

Item
2. Unregistered Sales of Equity Securities and Use of Proceeds.

None.

Item